HighSTEACS
Start date:June 2014 End date:
March 2017 Co-ordinated by:
University of Edinburgh & NHS Lothian
HighSTEACS is a randomised controlled trial, across 10 hospitals in NHS Lothian and NHS Greater Glasgow & Clyde, assessing patient outcomes before and after the implementation of high sensitivity Troponin assay
Research Team
EMERGE Research team
Cardiology Research Group
Aim
HighSTEACS is a randomised controlled trial, across 10 hospitals in NHS Lothian and NHS Greater Glasgow & Clyde, assessing patient outcomes before and after the implementation of high sensitivity Troponin assay. The primary endpoint is the one-year rate of cardiovascular death or recurrent myocardial infarction. Secondary endpoints include length of stay, unplanned coronary revascularisation, recurrent hospital admissions excluding ACS, bleeding events and non-cardiovascular death. There is also a sub-study at the ED, RIE and in one site in NHS Greater Glasgow and Clyde.
Trial Design
Prospective stepped wedge cluster randomised controlled trial
Eligibility criteria (summary)
Patients who present to the Emergency Department with suspected heart disease
Chief Investigator
Professor Nick Mills
Chair of Cardiology
Local PI
Professor Alasdair Gray
Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department
Research Team
Rachel O'Brien
Lead Research Nurse
Hedda Nyhus
Senior Research Nurse
Bev Goldberg
AMU Senior Research Nurse
Megan McGrath
Senior Research Nurse
More EMERGE Trials
Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.
NOVEL Study
Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions
People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.
Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.
KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.